Vincent Ma

Melanoma/Cutaneous Medical Oncologist @UWCarbone

[ACS Journal Cancer @JournalCancer]

New #OpenAccess review from @uw_medicine investigators summarizes the mechanistic rationale, preclinical evidence, and clinical development of intratumoral therapies in #melanoma.

https://t.co/p4Wuvk2BQD

@OncoAlert @diwakardavar @CureMelanoma

[OncLive.com @OncLive]

Percutaneous Hepatic Perfusion Could Boost Immunotherapy Response in Metastatic Melanoma @VincentMaMD @UWSMPH #melsm #oncology
https://t.co/LvxQzOJ1Rp

[Vincent Ma @VincentMaMD]

🧬Early ctDNA dynamics (3–4 wks can prognosticate outcomes in advanced melanoma (n=117) treated with ICI @JCOPO_ASCO

https://t.co/JI7bLoMnoL

⬇️ctDNA → ↑ response
• ORR OR 23.5
• DCR OR 30.6

⬇️ ctDNA → better survival
• PFS HR 0.18
• OS HR 0.28

@OncoAlert @ASCO

[Mario Balsa @MarioBalsaMD]

🧬 Sensitivity of circulating tumor DNA for detection of MRD recurrence in melanoma (56 pt, stage II to IV) @JCO_ASCO
https://t.co/YyFEdfdzZZ

🎯 Overall sensitivity 53.6%
💥 Strongly site-dependent: highest in LN (87.5%, P = .003) and liver (87.5%, P = .034), lowest in brain (33.3%, P = .248)

Minimal disease, maximal nuance. Sensitivity is contextual 🧠

@OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM @ASCO

[ACS Journal Cancer @JournalCancer]

New and #OpenAccess from @VincentMaMD et al: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

https://t.co/5y20Uh2wXb

[Vincent Ma @VincentMaMD]

Landmark results from the #NADINA trial, presented at #ASCO24! A study that is paving the way for response adapted treatment of melanoma. #Neoadjuvant #Immunotherapy #ASCO24 @ASCO @OncoAlert

[NEJM @NEJM]

Presented at #ASCO24:

Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: https://t.co/ZxWxo2qgNy

[Vincent Ma @VincentMaMD]

Great job @danny_trotier for this review article on managing periorbital skin malignancies! @uw_hemeoncpc @frontoncology

[Frontiers - Oncology @FrontOncology]

New research: Review of recent advances in managing periocular skin malignancies: Management of cutaneous malignancies can be particularly challenging when they are located in the periocular region. The standard of care for localized disease is… https://t.co/SGfQPjW5Z3 #oncology

[Vincent Ma @VincentMaMD]

Major milestone today! @US_FDA approves lifileucel, an autologous tumor infiltrating lymphocyte therapy, for previously treated advanced melanoma. This is the first in its class of cellular therapies for solid tumors.

[Vincent Ma @VincentMaMD]

@Samantha_July01 @OncLive @UWCarbone Our pilot study (NCT06199713) is accruing unresectable stage III/IV melanoma patients with baseline PET/CT who plan to be treated with ICI

[Vincent Ma @VincentMaMD]

Thank you @OncLive! We are excited to have our pilot study (NCT06199713) active and openly accruing patients with advanced melanoma at @UWCarbone

[OncLive.com @OncLive]

18F-FDG PET/CT May Serve as Early Interval Response Assessment Tool in Patients Receiving Combinatorial ICI Therapy. @VincentMaMD @UWCarbone #oncology
https://t.co/v2GQRSRii4

[OncoAlert @OncoAlert]

The OncoAlert 🚨 Newsletter Now OUT
Covering Dec 30-January 4, 2024

REGISTER at:
https://t.co/QFM2SYXqbg or https://t.co/hwvqbilbLO

Discussing:
✅2023 FDA Approvals🇺🇸
✅ #BreastCancer Screening
✅SECOMBIT in #Melanoma 🧬
✅TheraP in #ProstateCancer ☢️💊
✅COMBAT in Prostate #cancer
✅SBRT in RCC and more

@ASCO @VivekSubbiah @jsoriamd @drgandara @gerlach_d @bmassutis @dr_alphalyrae @KRHornberger @BarlundMaarit @birthandbiology @OmidHamidMD @PAscierto @mjuanfi81 @VincentMaMD @Hildur10016016 @PGrivasMDPhD @SuzanneColeMD @MattGalsky @koshkin85 @DrYukselUrun @Prof_IanD @dralvaropinto @newsincancer @CalaisJeremie @PeterMacRes @_ShankarSiva @radioncoluis @MeritxellMolla @matteolambe @aftimosp @JaniceTNBCmets @neerajaiims @amerseburger @scserendipity1 @HenningWillers @Icro_Meattini @CancerCareMASCC @VJOncology @high5md @mirrorsmed

#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @yekeduz_emre @HHorinouchi @FadiHaddad_MD @FuenteApolo @Abdallah81MD
@ElisaAgostinett

[Vincent Ma @VincentMaMD]

4-year survival updates! Although not a comparative trial between treatment arms, SECOMBIT appears to reaffirm the preferential use of doublet IO as first line followed by BRAFi/MEKi at progression in patients with metastatic BRAF-mutated melanoma. @NatureComms

[Omid Hamid MD @OmidHamidMD]

congrats @PAscierto a landmark paper illuminating the way for BRAF therapy in #melanoma #immunotherapy @NatureComms A must read !!!
https://t.co/9uTTrhSQir

[Vincent Ma @VincentMaMD]

Thank you @AIMatMelanoma! I am honored to discuss updates in melanoma care to the Wisconsin community with my colleagues, Drs Mark Albertini, Gloria Xu, and @neuman_heather. @UWCarbone @uw_medicine @uw_hemeoncpc

[AIM at Melanoma Foundation @AIMatMelanoma]

University of Wisconsin Carbone Cancer Center https://t.co/BRkWsJNv5k

[Vincent Ma @VincentMaMD]

Another FDA approved first-line PD-1 inhibitor treatment option for patients with advanced Merkel cell carcinoma

[Hussein Tawbi, MD, PhD @HTawbi_MDPhD]

Incredible achievement positive Phase 3 trial with TIL congrats @HaanenJohn & colleagues @NKI. Game changer/new era to improve patient outcomes. FDA approval never too soon! Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma | NEJM https://t.co/mTjCqwGp5v

[Frontiers - Immunology @FrontImmunol]

New Research: Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab: Background

Standard combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for advanced stage melanoma followed… https://t.co/BqtFnZScLJ #immunology

[Society for Immunotherapy of Cancer @sitcancer]

Thanks to Vincent T. Ma, MD @uwsmph for joining #SITC at #ASCO22 and for his assistance with the recaps of the scientific highlights of some of the groundbreaking IO sessions/abstracts for our members. #immunotherapy #Immune2Cancer #CIM22 #EndCancer

[Vincent Ma @VincentMaMD]

@US_FDA approves its newest checkpoint inhibitor, relatlimab (LAG-3 inhibitor), in combo with nivo for advanced stage melanoma. Recent RELATIVITY-047 results of nivo+rela vs nivo: mPFS (10.2 vs 4.6 mo), mOS (NR vs 34.1 mo), G3/4 trAEs (21.1% vs 11.1%)

[Jason Luke, MD, FACP, FASCO @jasonlukemd]

Major bummer that the #melanoma bem-peg (IL2) + nivo is a neg trial. Field opinion was split on this & the minimal phase 2 development/monoRx was a red flag. Hope this does not halt the dev of novel IL2's & other cytokines which are still promising.
https://t.co/j1rlYkCuX4

[Vincent Ma @VincentMaMD]

FDA finally approves tebentafusp (KIMMTRAK) as the FIRST systemic treatment for unresectable/metastatic uveal melanoma! #tebentafusp #KIMMTRAK #Immunocore

[Immunocore @Immunocore]

We are proud to be able to announce that our TCR therapy has been formally approved by the @US_FDA Full announcement: https://t.co/Z8gX78sWf9